Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy

被引:93
作者
Devillier, Raynier [1 ]
Coso, Diane [1 ]
Castagna, Luca [1 ,2 ]
Rossi, Isabelle Brenot [3 ]
Anastasia, Antonella [2 ]
Chiti, Arturo [4 ]
Ivanov, Vadim [1 ]
Schiano, Jean Marc [1 ]
Santoro, Armando [2 ]
Chabannon, Christian [1 ,5 ,6 ]
Balzarotti, Monica [2 ]
Blaise, Didier [1 ,5 ,6 ]
Bouabdallah, Reda [1 ]
机构
[1] Inst J Paoli I Calmettes, Dept Hematol, Transplantat & Cell Therapy Program, F-13009 Marseille, France
[2] Ist Clin Humanitas, Humanitas Canc Ctr, Hematol Unit, Milan, Italy
[3] Inst J Paoli I Calmettes, Dept Nucl Med, F-13009 Marseille, France
[4] Ist Clin Humanitas, Humanitas Canc Ctr, Nucl Med Unit, Milan, Italy
[5] Inst J Paoli I Calmettes, INSERM, CBT 510, Ctr Invest Clin Biotherapie, F-13009 Marseille, France
[6] Univ Aix Marseille, Fac Med, Inst J Paoli I Calmettes, Marseille, France
来源
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2012年 / 97卷 / 07期
关键词
Hodgkin's lymphoma; PET; outcome; relapsed refractory; ASCT; HIGH-DOSE CHEMOTHERAPY; PROGNOSTIC-FACTORS; FDG-PET; DISEASE; MULTICENTER; FAILURE; SCORE;
D O I
10.3324/haematol.2011.056051
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background High-dose chemotherapy followed by autologous stem cell transplantation is the standard treatment for relapsed and/or refractory Hodgkin's lymphoma although half of patients relapse after transplantation. Predictive factors, such as relapse within 12 months, Ann-Arbor stage at relapse, and relapse in previously irradiated fields are classically used to identify patients with poor outcome. Recently, 18-fluorodeoxyglucose positron emission tomography has emerged as a new method for providing information to predict outcome. The aim of this study was to confirm the predictive value of positron emission tomography status after salvage therapy and to compare single versus tandem autologous stem cell transplantation in patients with relapsed and/or refractory Hodgkin's lymphoma. Design and Methods We report a series of 111 consecutive patients with treatment-sensitive relapsed and/or treatment-refractory Hodgkin's lymphoma who achieved complete (positron emission tomography-negative group) or partial remission (positron emission tomography-positive group) at positron emission tomography evaluation after salvage chemotherapy and who underwent single or tandem autologous stem cell transplantation. Results Five-year overall and progression-free survival rates were 81% and 64%, respectively. There were significant differences in 5-year progression-free survival (79% versus 23%; P<0.001) and 5-year overall survival (90% versus 55%, P=0.001) between the positron emission tomography-negative and -positive groups, respectively. A complete response, as determined by positron emission tomography evaluation, after salvage therapy predicted significantly better 5-year overall survival rates in both intermediate (91% versus 50%; P=0.029) and unfavorable (89% versus 58%; P=0.026) risk subgroup analyses. In the positron emission tomography-positive subgroup, tandem transplantation improved 5-year progression-free survival from 0% (in the single transplantation group) to 43% (P=0.034). Multivariate analysis showed that positron emission tomography status (hazard ratio: 5.26 [2.57-10.73]) and tandem transplantation (hazard ratio: 0.39 [0.19-0.78]) but not risk factors at relapse (hazard ratio: 1.77 [0.80-3.92]) significantly influenced progression-free survival, while only tomography status significantly influenced overall survival (hazard ratio: 4.03 [1.38-11.75]). Conclusions In patients with relapsed/refractory Hodgkin's lymphoma responding to prior salvage therapy, positron emission tomography response at time of autologous stem cell transplantation favorably influences outcome and enables identification of patients requiring single or tandem transplantation.
引用
收藏
页码:1073 / 1079
页数:7
相关论文
共 30 条
[11]   ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial [J].
Federico, Massimo ;
Luminari, Stefano ;
Iannitto, Emilio ;
Polimeno, Giuseppe ;
Marcheselli, Luigi ;
Montanini, Antonella ;
La Sala, Antonio ;
Merli, Francesco ;
Stelitano, Caterina ;
Pozzi, Samantha ;
Scalone, Renato ;
Di Renzo, Nicola ;
Musto, Pellegrino ;
Baldini, Luca ;
Cervetti, Giulia ;
Angrilli, Francesco ;
Mazza, Patrizio ;
Brugiatelli, Maura ;
Gobbi, Paolo G. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) :805-811
[12]   Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy:: Results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 trial [J].
Fermé, C ;
Mounier, N ;
Diviné, M ;
Brice, P ;
Stamatoullas, A ;
Reman, O ;
Voillat, L ;
Jaubert, J ;
Lederlin, P ;
Colin, P ;
Berger, F ;
Salles, G .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (02) :467-475
[13]   Tandem transplant of peripheral blood stem cells for patients with poor-prognosis Hodgkins's disease or non-Hodgkin's lymphoma [J].
Fitoussi, O ;
Simon, D ;
Brice, P ;
Makke, J ;
Scrobohaci, ML ;
Triki, TB ;
Hennequin, C ;
Fermé, C ;
Gisselbrecht, C .
BONE MARROW TRANSPLANTATION, 1999, 24 (07) :747-755
[14]   Early interim 2-[18F]Fluoro-2-Deoxy-D-Glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma:: A report from a joint Italian-Danish study [J].
Gallamini, Andrea ;
Hutchings, Martin ;
Rigacci, Luigi ;
Specht, Lena ;
Merli, Francesco ;
Hansen, Mads ;
Patti, Caterina ;
Loft, Annika ;
Di Raimondo, Francesco ;
D'Amore, Francesco ;
Biggi, Alberto ;
Vitolo, Umberto ;
Stelitano, Caterina ;
Sancetta, Rosario ;
Trentin, Livio ;
Luminari, Stefano ;
Iannitto, Emilio ;
Viviani, Simonetta ;
Pierri, Ivana ;
Levis, Alessandro .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (24) :3746-3752
[15]   Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma [J].
Jabbour, Elias ;
Hosing, Chitra ;
Ayers, Gregory ;
Nunez, Rodolfo ;
Anderlini, Paolo ;
Pro, Barbara ;
Khouri, Issa ;
Younes, Anas ;
Hagerneister, Fredrick ;
Kwak, Larry ;
Fayad, Luis .
CANCER, 2007, 109 (12) :2481-2489
[16]   Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma:: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG) [J].
Josting, A ;
Rudolph, C ;
Mapara, M ;
Glossmann, JP ;
Sienawski, M ;
Sieber, M ;
Kirchner, HH ;
Dörken, B ;
Hossfeld, DK ;
Kisro, J ;
Metzner, B ;
Berdel, WE ;
Diehl, V ;
Engert, A .
ANNALS OF ONCOLOGY, 2005, 16 (01) :116-123
[17]   New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's Lymphoma Study Group [J].
Josting, A ;
Franklin, J ;
May, M ;
Koch, P ;
Beykirch, MK ;
Heinz, J ;
Rudolph, C ;
Diehl, V ;
Engert, A .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :221-230
[18]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[19]   DOSE INTENSIFICATION WITH AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN RELAPSED AND RESISTANT HODGKINS-DISEASE - RESULTS OF A BNLI RANDOMIZED TRIAL [J].
LINCH, DC ;
WINFIELD, D ;
GOLDSTONE, AH ;
MOIR, D ;
HANCOCK, B ;
MCMILLAN, A ;
CHOPRA, R ;
MILLIGAN, D ;
HUDSON, GV .
LANCET, 1993, 341 (8852) :1051-1054
[20]   Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease [J].
Milpied, N ;
Fielding, AK ;
Pearce, RM ;
Ernst, P ;
Goldstone, AH .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (04) :1291-1296